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ChemotherapyThe authors report an unusual case of primary central nervous system lymphoma presenting with
isolated pupil-involved oculomotor nerve palsy. Magnetic resonance imaging demonstrated leptome-
ningeal involvement of the midbrain and interpeduncular cistern, a single hypothalamic lesion, and
intraventricular involvement. Diffuse large B-cell lymphoma was conﬁrmed by stereotactic intraven-
tricular biopsy. Combination chemotherapy with methotrexate, vincristine, procarbazine and rituximab
was instituted with resolution of oculomotor nerve palsy and complete disease remission. An
interdisciplinary approach involving neurosurgeons, neuroradiologists, neuropathologists and neurol-
ogists is crucial in the management of primary central nervous system lymphoma.
Crown Copyright © 2014 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Primary central nervous system lymphoma (PCNSL) is a rare,
extra-nodal form of non-Hodgkin lymphoma accounting for 2.4% of
all primary brain tumours. In immunocompetent patients, PCNSL
commonly presents with a solitary lesion in the cerebral hemi-
spheres, basal ganglia, or periventricular region. Focal neurological
deﬁcits (70%), neuropsychiatric symptoms (43%) and symptoms of
increased intracranial pressure (33%) are the commonest forms of
presentation [1]. We present the rare case of a patient with PCNSL
presenting with isolated oculomotor nerve palsy (ONP). Combina-
tion chemotherapy and intrathecal methotrexate was instituted
with complete disease remission and resolution of ONP. Third nerve
palsy as a presenting symptom should be considered by clinicians
in PCNSL, especially given its increasing incidence. Additionally, we




This 42 year-old male presented with sudden obscuration of his
vision due to an inability to lift his right eyelid. On manual elevationial support to declare. The
ine Centre, PO Box 2900,
; fax: +61 3 9288 3350.
r Inc. This is an open access articleof the right eyelid, his partner noticed that his right pupil was
signiﬁcantly larger than the left, a previously absent ﬁnding. The
patient also complained of double vision. This was on a background
of intermittent headaches, nausea and vomiting over the preceding
two months. He denied any preceding trauma and any upper or
lower limb neurological symptoms. He had no signiﬁcant past
medical history and did not take any regular medications. On
examination, his right eyelid was partially ptosed. The right pupil
was dilated (8 mm) compared to the left (5 mm). Direct and
consensual pupillary light reﬂexes were sluggish on the right
compared to the left. Adduction, elevation and depression of the
right eye were impaired, while abduction and intorsion was intact.
Visual acuity was 6/6 bilaterally and there were no abnormalities
seen on fundoscopy and perimetry testing for visualﬁeld defects. The
remainder of the cranial nerve and neurological exam was
unremarkable. There was no palpable lymphadenopathy.Investigation and diagnosis
Given the pupil-involved ONP, contrast-enhanced computed
tomography (CT) and computed tomography angiogram (CTA) of
the brain were performed. No saccular aneurysmswere identiﬁed on
CTA. On contrast-enhanced CT and subsequent magnetic resonance
imaging (MRI), a leptomeningeal nodular and irregular enhancement
encasing the midbrain involving the interpeduncular cistern was
demonstrated. Additionally, a T1-isointense, T2-isointense hypotha-
lamic lesion measuring 12 mm × 11 mm × 11 mm was noted. This
lesion was homogeneously-enhancing with intravenous gadolinium
contrast. A further intraventricular lesion centred on the septumunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Axial (A to C, E–G) and sagittal (D, H) contrast-enhanced, T1-weighted, magnetic resonance imaging pre-chemotherapy (A–D) and post-chemotherapy (E–H). Interval
disease remission demonstrated by resolution of the nodular, homogeneously-enhancing lesion centred in the septum pellucidum (A, arrow &D, arrow) and hypothalamus (B,
arrowhead & D, arrowhead). Leptomeningeal enhancement encasing midbrain and interpeduncular cistern (C, arrow & D, curved arrow) is similarly resolved post-
chemotherapy. Note that there is no appreciable hydrocephalus.
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with widespread irregular ependymal enhancement of the fourth
ventricle and bilateral foramen of Luschka (Fig. 1). There was no
hydrocephalus and contrast-enhanced MRI of the spine was normal
without leptomeningeal or intramedullary involvement. A working
diagnosis of CNS lymphoma was made and the haematology
department at the institution was consulted.
Further investigations were conducted to conﬁrm and determine
the extent of PCNSL. Cerebrospinal ﬂuid (CSF) analysis via lumbar
puncture revealed a cell count of 2 × 106/L erythrocytes and
93 × 106/L leukocytes comprising 86% lymphocytes and 14% poly-
morphs. CSF protein was elevated (1.22 g/L) and glucose concentra-
tionwas at the lower range of normal (2.7 mmol/L). CSF cytology and
ﬂow cytometry was not suggestive of lymphoma. The serum full
blood and white cell differential count, human immunodeﬁciency
virus (HIV) antigen/antibody test, hormonal panel, serum lactate
dehydrogenase and testicular ultrasound were normal. CT of the
chest, abdomen and pelvis did not demonstrate lymphadenopathy.
Bone marrow aspirate and trephine (BMAT) did not reveal
lymphomatous inﬁltration.
An image-guided, endoscopic intraventricular biopsy was under-
taken via a left frontal burrhole. At operation, extensive grey-white
tumour lining the lateral ventricles bilaterally across the septum
pellucidum was visualized and biopsied. Histopathological exami-
nation revealed sheets of atypical cells with hyperchromatic nuclei
and scant cytoplasm of lymphoid origin. Immunohistochemistry was
strongly positive for CD20 and mildly positive for CD3 (Fig. 2). A
deﬁnitive diagnosis of PCNSL (diffuse large B-cell lymphoma
subtype) was made. Post histopathological diagnosis, an Ommaya
reservoir was inserted.
Management and clinical progress
The patient recovered well postoperatively and was commenced
on combination chemotherapy by the haematology department. The
protocol consisted of ﬁve 14-day cycles of R-MPV (Rituximab,
Methotrexate, Procarbazine, Vincristine) with intra-Ommaya meth-
otrexate between cycles [2]. The patient completed chemotherapy
without major side effects, with resolution of his ONP. Post-
chemotherapy brainMRI threemonths post-diagnosis demonstratedcomplete disease remission (Fig. 1). Given the patient’s relatively
young age and good performance status, whole-brain radiotherapy
(WBRT) followed by high-dose cytarabine will be instituted with
curative intent.Discussion
This is an unusual case of PCNSL presenting in the form of isolated
ONP. ONP was most likely secondary to leptomeningeal lymphoma
causing extrinsic compression of theOcN as it exited themidbrain via
the interpeduncular cistern. This is reﬂected as irregular contrast
enhancement of the interpeduncular cistern encasing the midbrain
on contrast-enhanced MRI of the brain. A systematic review of the
current literature revealed six previous cases of PCNSL presenting as
isolatedONP [3–8]. In 1967, Bravermanet al. [4] reported the case of a
59 year-old female with autopsy evidence of PCNSL in the basal
leptomeninges and septum pellucidumwith contiguous extension to
the corpus callosumsuperiorly andhypothalamus caudally. The cause
of ONP and distribution of intracranial lymphoma is very similar to
the present case and is consistentwith the predilection of intracranial
lymphoma to involve the periventricular white matter and basal
ganglia. In caseswhere diagnostic imagingwas performed [3,5–8], all
but one [6] revealed abnormalities of the cisternal or cavernous OcN
accounting for ONP. Given advances in MRI of the OcN, and the near-
universal enhancement of PCNSL post-contrast administration,
contrast-enhanced MRI is a sensitive modality for demonstrating
OcN involvement in cases of PCNSL presenting with isolated ONP.
Diagnostic evaluation of PCNSL focuses on histopathological
assessment and conﬁrmationof the absence of systemic involvement.
The latter is crucial in therapy and prognostics as secondary central
nervous system lymphoma is an aggressive, terminal form of non-
Hodgkin lymphoma with a median survival of six months. As
presented in the current case, thorough evaluation of suspected
PCNSL with laboratory tests and diagnostic imaging in accordance
with the International PCNSL Collaborative Group [9] is required,
especially given reports of occult systemic disease in cases mis-
diagnosed as PCNSL. Prompt referral to the haematologists and
oncologists, together with an interdisciplinary approach to diagnosis
and treatment provides the best possible patient outcome.
Fig. 2. Neoplastic cells comprising of sheets of atypical cells, hyperchromatic nuclei and scant cytoplasm. Frequent apoptotic debris, mitotic ﬁgures and focal necrosis noted
(haematoxylin and eosin; original magniﬁcation ×10 [A] and ×20 [B]). Neoplastic cells are positive-staining for CD20 (C; Immunohistochemistry with haematoxylin and eosin
counterstain; original magniﬁcation ×20).
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multiple on-going phase II trials. High incidences of neurotoxicity,
especially in the elderly, have resulted in a shift away fromWBRT as
primary treatment towards regimens of combination chemother-
apy with methotrexate as an anchor chemotherapeutic agent.
Importantly, WBRT administered after combination chemotherapy
does not extend overall survival in newly-diagnosed PCNSL [10]
and there is a contemporary tendency to reserve WBRT to non/
partial-responders to chemotherapy or relapses of PCNSL. An
example is the protocol established by Morris et al. [2] and applied
to the currently presented case. In this protocol induction
chemotherapy with R-MPV followed by reduced or standard
WBRT and consolidation cytarabine achieved a two-year progres-
sion free survival of 77%. Overall survival was not reached at a
median of 5.9 years follow up. The use of intrathecal methotrexate
remains an area of controversy, as retrospective studies have not
shown a survival beneﬁt [11], and the use of systemic high-dose
methotrexate-based regimens likely result in attainment of
therapeutic methotrexate levels in the CSF [12]. There are currently
no prospective randomized trials speciﬁcally investigating the use
of intrathecal methotrexate. Of note, leptomeningeal dissemination
in PCNSL is not a negative prognostic factor in terms of overall
survival and progression-free survival [13]. Neurosurgical inter-
vention for PCNSL has traditionally been recommended in the form
of tissue biopsy and themanagement of neurosurgical emergencies.
However, in a secondary analysis of a phase III trial, Weller et al.
[14] demonstrated improved overall and progression-free survival
in patients undergoing subtotal or gross total resection as
compared to those undergoing biopsy. Therefore, cytoreductive
surgery for PCNSL, especially in cases where solitary lesions can be
safely resected, should be considered in the management of PCNSL.
Conclusion
In conclusion, isolated ONP is a rare presentation of PCNSL that
neurosurgeons should be aware of. An interdisciplinary approach
involving neurosurgeons, neuroradiologists, neuropathologists and
neurologists is crucial, and thorough diagnostic evaluation includingcontrast-enhanced MRI and exclusion of systemic disease is
paramount for disease management and prognostication.
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